Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo with standard first-line therapy in metastatic breast cancer
ISRCTN72153214Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Sorafenib plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Progression-free survival. Started Nov 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN72153214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72153214.